SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as social media mentions draw comparisons to previous meme stock rallies, particularly with *another* stock experiencing high short interest. The community is actively discussing potential short squeezes, options activity, and the influence of key figures. Some traders express frustration with perceived market manipulation and are debating the company's long-term prospects.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors react to news of a multi-year, multi-million dollar partnership with Lumen Technologies to boost enterprise AI. Community discussions revolve around the significance of this deal for Palantir's commercial growth and its role in the AI infrastructure landscape, with some highlighting the potential for a breakout while others question the valuation. Broader market sentiment and upcoming earnings are also contributing to the stock's current buzz.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid ongoing discussions about its potential and future outlook, with the community expressing excitement and using the hashtag $WAGMI (We Are All Gonna Make It) to signal a shared belief in its success. Discussions include potential new all time highs. Additionally, newer projects on the Solana blockchain are being discussed.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is trending as investors anticipate upcoming earnings, where AI strategy and potential stock splits are key discussion points, with many expecting a strong report. Community members are actively trading options, while also analyzing potential price targets and support levels. Overall sentiment suggests anticipation for Meta's earnings and broader tech sector movements.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with community members actively discussing potential positive outcomes and a possible run-up to new highs. Optimism is fueled by speculation of a 'triple beat' on revenue, EBITDA, and EPS, as well as potential rate cuts and the possibility of S&P 500 inclusion.  Some traders are wary of a potential post-earnings dip, while others remain bullish on the company's long-term prospects.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction in the project's long-term growth and potential within the Solana ecosystem. The community emphasizes holding through market volatility and building a decentralized future. Discussions also highlight how to purchase WAGMI, with community members providing tutorials and guidance.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending amid discussions about a potential deal with Australia's Larvotto Resources and the implications for U.S. antimony supply. Community members are debating the deal's valuation, potential government involvement, and UAMY's strategic position as a domestic supplier. Bullish sentiment persists due to UAMY's existing contracts and potential growth, despite deal uncertainties and sector volatility.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin ($CRO) is trending amid mixed sentiment; while some community members express frustration with its price action and perceived underperformance compared to Bitcoin and Binance Coin ($BNB), others highlight its potential due to recent developments like Cronos partnerships and anticipation of a spot ETF. Many are also discussing the meme coin $CAW and its relationship to $CRO. The recent filing for a National Trust Bank Charter by Crypto.com/us is seen as a bullish sign for secure custody and staking.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recent $150M capital raise and a $5M production order, signaling a move towards full-scale commercial production and expansion in the AI photonics space. The community is discussing the potential for partnerships with major players like Meta and the impact of photonics technology on AI data centers, drawing comparisons to other high-growth tech companies. The raise gives POET a strong cash position to execute on its growth plans.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

$MERY is trending as community members highlight its strong correlation with $CRO, anticipating potential gains. Some users point to a new listing and hint at upcoming announcements and a new game. Community buzz suggests that a crypto.com campaign could bring increased attention to the token.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?

Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy

Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?

The mean of analysts' price targets for Immunovant (IMVT) points to a 137.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus 

Shares of Immunovant, Inc. (IMVT) traded 2% higher on Thursday morning after the company reported a narrower-than-expected first-quarter loss.The clinical-stage immunology company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.immunovant.com/investors/news-events/press-releases/detail/73/immunovant-provides-corporate-updates-and-reports-financial">reported</a> a net loss of $0.64 per share for the quarter compared to a loss of $0.52 for the corresponding quarter of 2024, and lower than an estimated loss of $0.72 per share, as per Finchat data.The company’s increased research and development expenses, as well as general and administrative expenses, weighed on its bottom line, with the net loss widening to $106.45 million.Immunovant is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.Its candidate IMVT-1402 is being developed for the treatment of multiple illnesses, including Graves’ disease (GD), difficult-to-treat Rheumatoid Arthritis (D2T RA), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Sjögren’s Disease (SjD).The company ended the quarter with cash and cash equivalents totalling approximately $714 million, expected to provide runway till 2027.Last month, Immunovant announced changes to its leadership as part of its parent company, Roivant, increasing operational involvement and strategic oversight of the company.The company appointed Eric Venker as CEO, replacing Pete Salzmann, and Tiago Girao as CFO, replacing Renee Barnett.On Stocktwits, retail sentiment around IMVT stayed within the ‘neutral’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_10_09_02_AM_png_50dfeaa22a.webp" alt="IMVT's Sentiment Meter and Message Volume as of 10:10 a.m. ET on May 29, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>IMVT's Sentiment Meter and Message Volume as of 10:10 a.m. ET on May 29, 2025 | Source: Stocktwits</figcaption></figure> According to data from Koyfin, 12 of the 15 analysts covering Immunovant rate it a ‘Buy’ or higher, while three rate it a ‘Hold’. The stock has an average price target of $45.15, representing an upside of over 200% from its current share price.<a href="https://stocktwits.com/symbol/IMVT">IMVT stock</a> is down by about 43% this year and by about 51% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/iridium-partners-with-syniverse-to-launch-global-satellite-service/ch0AYoSRbto">Iridium Partners With Syniverse To Launch Global Satellite Service: Retail Stays Confident</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence

The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share.

Equity

Immunovant, Inc. (IMVT) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.immunovant.com/investors/news-events/press-releases/detail/72/immunovant-announces-next-phase-of-growth-with-roivant">announced</a> on Monday that Roivant President Eric Venker will succeed Pete Salzmann as the new CEO, following Salzmann's retirement from his role.Venker, meanwhile, will continue to serve on Immunovant’s Board of Directors.Tiago Girao will be the company’s new CFO, replacing Renee Barnett. Girao was formerly the CFO of biopharmaceutical company Telavant Holdings.Immunovant stated that these changes are part of its parent company, Roivant, increasing operational involvement and strategic oversight of the company.&nbsp; George Migausky has stepped down from the Immunovant board of directors, and Robert Susman and Jacob Bauer have joined the board, effective April 18, 2025, the company added.Immunovant is a clinical-stage immunology company developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.The company now plans to study its IMVT-1402, an anti-FcRn antibody for the treatment of IgG-mediated autoimmune diseases, in the treatment of Sjögren’s disease and Cutaneous Lupus Erythematosus as well. No therapies have been explicitly approved for the treatment of Sjögren’s disease to date, it said.The company said it is beginning to conclude development activities for batoclimab, an anti-FcRn monoclonal antibody.Venker said that Immunovant has shown “compelling efficacy data” in clinical trials for batoclimab in Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Graves’ Disease, and Thyroid Eye Disease.Immunovant said that its current cash balance is expected to provide a runway till 2027.On Stocktwits, retail sentiment around the stock jumped from ‘bearish’ to ‘bullish’ territory while message volume remained at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:644/147;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_21_at_8_09_32_AM_png_03ceffe093.webp" alt="IMVT's Sentiment Meter and Message Volume as of 8:10 a.m. ET on April 21, 2025 | Source: Stocktwits" width="644" height="147"><figcaption>IMVT's Sentiment Meter and Message Volume as of 8:10 a.m. ET on April 21, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/IMVT">IMVT stock</a> is down by over 40% so far this year and by over 45% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-decline-as-trump-tariffs-cloud-earnings-season/chQiK8CRbQg">Dow Futures Decline As Trump’s Tariffs Cloud Earnings Season: Tech Bull Says ‘White House Needs Trade Deals Done Quick’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated

Immunovant stated that these changes are part of its parent entity, Roivant, increasing operational involvement and strategic oversight of the company. 

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24...

What the Options Market Tells Us About Immunovant

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Immunovant Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

IMVT
Immunovant Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IMVT News

IMVTImmunovant Inc